Joint Corp (JYNT) Stock Analysis

Verdict: HOLD

Strategic pivot to an asset-light franchise model supported by aggressive insider buying at $8.50 suggests a low-downside turnaround play.

Investment score: 64/100

Analysis as of

Is Joint Corp stock worth reviewing? AI model thesis

JYNT is transitioning from a capital-heavy corporate clinic operator to a pure-play franchisor. While trailing revenue looks poor due to refranchising, the 80% gross margin and extreme insider confidence at current prices create a favorable risk/reward setup.

7-factor investment score

Joint Corp opportunities and risks

What speaks for JYNT

What speaks against JYNT

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
JYNT40.6x2.3x44.6x79.9%5.7%2.0%
ARDT9.9x0.2x3.9x49.7%2.1%15.8%
USPH826.2x1.3x12.5x20.4%0.2%6.8%
NUTX8.5x0.8x3.0x47.5%11.0%37.0%
TOIn/a0.8xn/a14.8%-8.0%-5.6%
CYHn/a0.0x2.1x53.7%-0.4%-50.4%
Peer median8.5x0.8x3.0x47.5%0.2%6.8%

Frequently asked questions about Joint Corp (JYNT)

Is JYNT stock a good investment?

The cached TradeMates AI model rates Joint Corp as HOLD with an investment score of 64/100. JYNT is transitioning from a capital-heavy corporate clinic operator to a pure-play franchisor. While trailing revenue looks poor due to refranchising, the 80% gross margin and extreme insider confidence at current prices create a favorable risk/reward setup. This is algorithmic model output, not personal investment advice.

Is JYNT stock a buy?

The TradeMates model verdict for JYNT is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.